Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Alnylam Pharmaceuticals, Inc. (ALNY) – Alnylam Pharmaceuticals, Inc. Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Alnylam Pharmaceuticals (ALNY) trades at $293.17, up 1.73% on the day, with a bullish technical signal and strong analyst support. The company shows a remarkable financial turnaround, moving from net losses to profitability, with 2025 revenue reaching $3.71B and net income of $313.75M. Recent news highlights portfolio diversification efforts, a strategic $2B AI collaboration with Inceptive to accelerate drug discovery, and positive clinical data for vutrisiran.
The outlook is positive with a consensus price target of $443.40 (51% upside), driven by revenue growth, margin expansion, and pipeline catalysts. Key risks include dependence on Amvuttra for revenue, high valuation multiples (P/E 73.88), and typical biotech execution risks. Wall Street sentiment is strongly bullish with 39 Buy ratings versus 1 Sell.
Read full analysis

Key Stats

  • Market Cap
    $39.26B
  • Sector
    Health
  • 3M Drawdown
    -18.07%
  • Enterprise Value
    $37.52B
  • Dividend Yield
    -
  • Typical Hold Time
    42 days
$292.59
52W Low: $278.09
18 Jun 2026
52W High: $491.22
20 Oct 2025

Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $39.26B, with an enterprise value of $37.52B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $278.09 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -18.07%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 42 days, indicating typical investor behavior on the platform.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.


People also bought


Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Key Stats

  • Market Cap
    $39.26B
  • Sector
    Health
  • 3M Drawdown
    -18.07%
  • Enterprise Value
    $37.52B
  • Dividend Yield
    -
  • Typical Hold Time
    42 days
$292.59
52W Low: $278.09
18 Jun 2026
52W High: $491.22
20 Oct 2025

Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $39.26B, with an enterprise value of $37.52B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $278.09 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -18.07%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 42 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!